Alexander Disease
Also known as: AxD, Fibrillary Astrocytopathy, Alexander's Disease
Alexander disease is a rare and often fatal neurological disorder characterized by the progressive destruction of white matter in the brain (leukodystrophy). It is caused by mutations in the GFAP gene, which encodes glial fibrillary acidic protein, a major component of astrocytes. The disease primarily affects the brain and spinal cord, leading to a range of neurological symptoms.
Imagine your brain has special helpers called astrocytes that keep everything tidy. In Alexander disease, the instructions for making these helpers are messed up, so they make a sticky substance that clogs up the brain and makes it hard to think, move, and grow.
Signs & Symptoms
- Seizures
- Developmental delay (in infants and children)
- Intellectual disability
- Spasticity
- Ataxia
- Hydrocephalus
- Megalencephaly (enlarged brain)
- Bulbar dysfunction (difficulty swallowing, speaking)
- Progressive motor and cognitive decline
Treatment Options
Symptomatic Management
SUPPORTIVESeizure Control (Antiepileptic Drugs)
MODERATELY EFFECTIVEPhysical Therapy
SUPPORTIVEOccupational Therapy
SUPPORTIVESpeech Therapy
SUPPORTIVEBaclofen or other anti-spasticity medications
MODERATELY EFFECTIVEGene Therapy (Experimental)
EXPERIMENTALDiagnosis
- MRI of the brain (shows characteristic white matter abnormalities)
- Genetic testing for GFAP mutations
- Brain biopsy (rarely needed, but can confirm the diagnosis)
History
Alexander disease was first described by W. Stewart Alexander in 1949, who identified characteristic pathological features in the brain of an affected infant.
Recent Breakthroughs
Advancements in Gene Therapy for Alexander Disease
Preclinical studies have shown promising results using adeno-associated virus (AAV) vectors to deliver functional GFAP genes, reducing Rosenthal fiber formation and improving neurological outcomes in animal models.
Identification of Novel Therapeutic Targets
Research has identified potential therapeutic targets aimed at reducing GFAP aggregation and promoting astrocyte health, offering new avenues for drug development.